Managing the High-Risk Patient, LDL & Beyond
Future and Contemporary Approaches


Back to top


Back to top

Program Description

This CME Event has been designed to provide health care professionals with the most current knowledge of the pathophysiology and prevalence of CVD in high risk patients. Focus will be on newly recognized mechanism in lipid disorders, namely PCSK9, that has made contributions to LDL homeostasis in the development of atherosclerosis and CVD. Currently available pharmacological strategies and emerging therapies using medical society guidelines and expert insight on applicable treatment targets, will be presented to help practitioners reduce cardiovascular disease risk for the patients, ultimately achieving better patient outcomes.

Learning Objectives

Explain the challenges of the high-risk person and the role of LDL and other lipid disorders in the development of atherosclerosis. Describe the mechanism of LDL production and the role of PCSK9 in homeostasis of LDL-C. Discuss the controversy in utilizing lipid goals in the management of the high-risk patient, compare and contrast available medical association guidelines.

Activity information

  • Duration: 1.5 hours you will earn 1.5 FREE AMA PRA Category 1 Credit(s)™

  • Based on Satellite Symposium held on November 21, 2014 in association with the 12th Annual World Congress on the Insulin Resistance, Diabetes & Cardiovascular Disease.

  • Date of release:  January 30th 2015

  • Date of expiration: January 30th, 2016

Target Audience

Cardiologists, endocrinologists, family physicians, internists, nurse practitioners, and other health care professionals interested in diabetes and CVD.

Back to top

Program Provided By

Metabolic Endocrine Education Foundation (MEEF)
PESI, Inc.
Metabolic Institute of America (MIA)

Back to top

Acknowledgement of Support

This CME activity is supported by an educational grant from Amgen

Back to top

To get started:

Login / Register

CME information

View Agenda

Course presentations

To Receive a Certificate for This CME Activity

View the presentations in this CME activity and Complete the evaluation. Your certificate will be mailed to you Upon satisfactory completion of these documents.

Faculty Disclosures and Conflicts of Interest

It is the policy of PESI, Inc., Aspen CME Services, Minnesota Pharmacists Association and the Metabolic Endocrine Education Foundation, accreditors of this live educational activity that anyone that can affect the content of an educational activity must provide disclosure of financial relationships that they or their partner may have with commercial supporters.  Speakers are also required to disclose if their presentation will contain information on off-labeled, investigational, or unapproved use of a product.  The planning faculty,  speakers, and moderators for this activity have provided the following information:

Last First Relationship
Asp Renee Nothing to disclose
Ballantyne Christie Grant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, GlaxoSmithKline, Genentech, Merck, Novartis, Pfizer, Regeneron, Roche, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA

Consultant- Abbott Diagnostics, Aegerion, Amarin, Amgen, Arena, Astra Zeneca, Cerenis, Esperion, Genentech, Genzyme, Kowa, Merck*, Novartis, Pfizer*, Resverlogix, Regeneron, Roche, Sanofi-Synthelabo
*Significant where noted (>10,000.); remainder modest (< 10,000).
Fazio Sergio Merck, Kowa, Lupin, Roche, Amarin, Sanofi, BASF & Genzyme=Consultant
Handelsman Yehuda Research, Consultant, Lecturer: Amarin, Amgen, AZ, BMS, BI, BI-Lilly, diaDeux, DSI, Eisai, Gilead, Grifols, GSK, Hamni, Intarcia, Janssen, LipoScience, Lexicon, Merck, Novo Nordisk, Sanofi Takeda, Vivus
Jones Peter Merck, Amgen & Sanofi/Regeneron=Consultant
Seley Jane Nothing to disclose
Zagha Maurice Nothing to disclose

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education, through the joint providership of PESI, Inc, and the Metabolic Endocrine Education Foundation (MEEF). PESI, Inc is accredited by the ACCME to provide continuing medication education for physicians.

AMA PRA Designation Statement
PESI, Inc designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to top

No part of this publication may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission © 2015 MEEF
For questions regarding this CME activity, please contact us

Back to top